Research ArticleClinical Studies

Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma

ABDELBASET BUHMEIDA, ANNIKA ÅLGARS, RAIJA RISTAMÄKI, YRJÖ COLLAN, KARI SYRJÄNEN and SEPPO PYRHÖNEN
Anticancer Research January 2006, 26 (1B) 455-462;

Article Information

vol. 26 no. 1B 455-462
PMID 
16739305
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received November 14, 2005
  • Accepted November 25, 2005
  • Published online January 1, 2006.
Copyright & Usage 
Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. ABDELBASET BUHMEIDA1,
  2. ANNIKA ÅLGARS1,
  3. RAIJA RISTAMÄKI1,
  4. YRJÖ COLLAN2,
  5. KARI SYRJÄNEN1 and
  6. SEPPO PYRHÖNEN1
  1. 1Department of Oncology and Radiotherapy, Turku University Hospital, University of Turku, Finland
  2. 2Department of Pathology, Turku University Hospital, University of Turku, Finland
  1. Correspondence to: Abdelbaset S. Buhmeida, MD, Dr. Med. Sci., Department of Oncology and Radiotherapy, Turku University Hospital, P.O. Box 52 (Savitehtaankatu 1), FIN-20521 Turku, Finland. Tel: +358 2 3337016, Fax: +358 2 313 2809, e-mail: abuhme{at}utu.fi

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Nuclear Size as Prognostic Determinant in Stage II and Stage III Colorectal Adenocarcinoma
ABDELBASET BUHMEIDA, ANNIKA ÅLGARS, RAIJA RISTAMÄKI, YRJÖ COLLAN, KARI SYRJÄNEN, SEPPO PYRHÖNEN
Anticancer Research Jan 2006, 26 (1B) 455-462;
Twitter logo Facebook logo Mendeley logo

Jump to section